{"case_name": "Hologic, Inc. et al v. Minerva Surgical, Inc.", "case_number": "20-925", "judge": "Magistrate Judge Sherry R. Fallon", "date": "09-26-2022", "ocr_text": "IN THE UNITED STATES DISTRICT COURT \nFOR THE DISTRICT OF DELAWARE \nHO LOGIC, INC., a Delaware corporation; ) \nand CYTYC SURGICAL PRODUCTS, ) \nLLC, a Massachusetts limited liability ) \ncompany, \nPlaintiffs, \nV. \nMJNERVA SURGICAL, INC., a \nDelaware corporation, \nDefendant. ) \n) \n) \n) \n) \n) \n) \n) \n) \n) C.A. No. 20-925-JFB-SRF\nMEMORANDUM OPINION \nPresently before the court in this patent infringement action is the motion to lift the stay \nfiled by plaintiffs Hologic, Inc. and Cytyc Surgical Products, LLC (together, \"Hologic\").1 (D.I. \n125)For the following reasons, the motion to lift the stay is GRANTED.\nI.BACKGROUND\nHologic initiated this action in July 2020, alleging infringement ofHologic's U.S. Patent\nNo. 9,095,348 (''the '348 patent\") by defendant Minerva Surgical, Inc. 's (\"Minerva\" ) redesigned \nEndometrial Ablation System (\"Redesigned EAS\"). (D.1. 1 at 111, 35, 61) The scope of the \nrelief sought for the alleged infringement is limited to monetary damages for the five-month \nperiod the Redesigned EAS was sold before the '348 patent expired. (Id) Specifically, Hologic \nseeks damages from the date Minerva first commercialized te Redesigned EAS on June 28, \n2018 to the date the '348 patent expired on November 19, 2018. (Id) \n1 The briefing and other filings associated with the pending motion to lift the stay are found at\nD.I. 125, D.I. 126, D.I. 127, D.I. 128, D.I. 129, and D.I. 130."}